U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H10ClN3O.ClH
Molecular Weight 236.098
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LAZABEMIDE HYDROCHLORIDE

SMILES

Cl.NCCNC(=O)C1=CC=C(Cl)C=N1

InChI

InChIKey=JMFKTFLARGGXCC-UHFFFAOYSA-N
InChI=1S/C8H10ClN3O.ClH/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C8H10ClN3O
Molecular Weight 199.638
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/12359039 | https://www.thepharmaletter.com/article/blow-for-roche-as-phase-iii-tempium-trials-are-discontinued

Lazabemide is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under clinical development against Parkinson's disease, Alzheimer's disease and as an aid to smoking cessation. The development of the drug was discontinued due to liver toxicity.

Originator

Curator's Comment: # Hoffmann-La Roche

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.091 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.
1990
Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.
1993 Oct
Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.
1994 Sep
Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
1999 Nov-Dec
Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex.
2003 Jul 11
Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.
2011 Dec 8
Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography.
2011 Jan 25
Patents

Patents

Sample Use Guides

In clinical trial against Parkinson's disease, lazabemide was administered orally at doses 25-200 mg/day
Route of Administration: Oral
Lazabemide inhibited recombinant human MAO-B with IC50 of 0.091 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:30:09 GMT 2023
Edited
by admin
on Fri Dec 15 15:30:09 GMT 2023
Record UNII
PI150J9ZX1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LAZABEMIDE HYDROCHLORIDE
JAN   USAN  
USAN  
Official Name English
LAZABEMIDE MONOHYDROCHLORIDE [MI]
Common Name English
LAZABEMIDE MONOHYDROCHLORIDE
MI  
Common Name English
LAZABEMIDE HYDROCHLORIDE [USAN]
Common Name English
RO 19-6327/001
Code English
RO-19-6327/001
Code English
LAZABEMIDE HCL
Common Name English
RO-196327001
Code English
2-PYRIDINECARBOXAMIDE, N-(2-AMINOETHYL)-5-CHLORO-, MONOHYDROCHLORIDE
Common Name English
N-(2-AMINOETHYL)-5-CHLORO-2-PYRIDINE-CARBOXAMIDE HYDROCHLORIDE
Systematic Name English
TEMPIUM
Brand Name English
LAZABEMIDE HYDROCHLORIDE [JAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C667
Created by admin on Fri Dec 15 15:30:09 GMT 2023 , Edited by admin on Fri Dec 15 15:30:09 GMT 2023
Code System Code Type Description
PUBCHEM
163727
Created by admin on Fri Dec 15 15:30:09 GMT 2023 , Edited by admin on Fri Dec 15 15:30:09 GMT 2023
PRIMARY
NCI_THESAURUS
C80968
Created by admin on Fri Dec 15 15:30:09 GMT 2023 , Edited by admin on Fri Dec 15 15:30:09 GMT 2023
PRIMARY
MERCK INDEX
m6719
Created by admin on Fri Dec 15 15:30:09 GMT 2023 , Edited by admin on Fri Dec 15 15:30:09 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL279390
Created by admin on Fri Dec 15 15:30:09 GMT 2023 , Edited by admin on Fri Dec 15 15:30:09 GMT 2023
PRIMARY
USAN
LL-81
Created by admin on Fri Dec 15 15:30:09 GMT 2023 , Edited by admin on Fri Dec 15 15:30:09 GMT 2023
PRIMARY
FDA UNII
PI150J9ZX1
Created by admin on Fri Dec 15 15:30:09 GMT 2023 , Edited by admin on Fri Dec 15 15:30:09 GMT 2023
PRIMARY
EPA CompTox
DTXSID4046739
Created by admin on Fri Dec 15 15:30:09 GMT 2023 , Edited by admin on Fri Dec 15 15:30:09 GMT 2023
PRIMARY
CAS
103878-83-7
Created by admin on Fri Dec 15 15:30:09 GMT 2023 , Edited by admin on Fri Dec 15 15:30:09 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY